Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Areteia will initiate Phase 3 trials of lead candidate, dexpramipexole, a potential first-in-class oral drug for eosinophilic asthma, in late 2022 Investors led by Bain Capital Life Sciences to invest up to $350 million in Series A financing Jorge Bartolome joins Areteia as CEO, bringing industry leadership experience in respiratory therapeutics PITTSBURGH, Pa. & SHORT …

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding Read More »